Enhancing Efficiency: Fast and Reliable Nitrite Content Analysis in Pharmaceutical Excipients With the ACQUITY™ QDa™ II Mass Detector

Importance of the Topic

Pharmaceutical products are at risk of carcinogenic N-nitrosamine formation when nitrite, a key precursor, reacts with amines under acidic conditions. Monitoring nitrite levels in excipients is a pragmatic approach to mitigate this risk, offering a rapid and sensitive alternative to complex nitrosamine assays. Routine screening of raw materials ensures consistent product safety and supports regulatory compliance.

Study Objectives and Overview

This study evaluates the long-term performance of the ACQUITY QDa II single quadrupole mass detector for fast, reliable quantitation of nitrite in common pharmaceutical excipients. Over 29 days and nearly 6 000 injections, the work aims to demonstrate:

• Instrument robustness and uptime under high-throughput conditions
• Method precision at trace levels (0.2–5.0 µg/g)
• Suitability of Empower CDS for compliant data reporting

Methodology

Five excipients—sorbitol, lactose monohydrate, maize starch, maltodextrin, and calcium carbonate—were derivatized with 2,3-diaminonaphthalene (DAN) to form a detectable triazole (NAT). Samples, process blanks, and spikes (0.2, 2.0, 5.0 µg/g) were prepared in triplicate. Calibration standards (0.5–12.5 ng/mL NAT) were bracketed throughout each sequence. Continuous selected ion recording (SIR) targeted m/z 170.1 for NAT, with system stability monitored via QC standards (acetaminophen, caffeine).

Instrumentation

ACQUITY Arc UHPLC with FTN-R Sample Manager coupled to ACQUITY QDa II Mass Detector
Column: ACQUITY UPLC HSS T3 2.1×100 mm, 1.8 µm at 45 °C
Mobile phases: 0.1% formic acid in water (A) and acetonitrile (B); flow 0.4 mL/min; 6 min runtime
ES+ source at 0.8 kV, 120 °C source, 400 °C desolvation
Data system: Empower 3.0 CDS

Main Results and Discussion

Calibration linearity (1/X) was excellent (R²>0.99), with blank subtraction managing baseline nitrite. The method delivered average recoveries of 94% across spikes, and only maize starch exhibited a consistent nitrite level (~0.14 µg/g). Other excipients were at or below detection limits governed by blank contamination (~0.041 ng/mL). System precision remained high: QC RSD<12.5% over 520 h, standard injections RSD<14.7%, and excipient spikes RSD<20%.

Benefits and Practical Applications

• Six-minute assay with µg/g sensitivity suitable for high sample throughput
• Minimal downtime—only 2 h maintenance over 676 h of operation
• Cost-effective alternative to traditional nitrite tests with poor sensitivity or long runtimes
• Empower CDS reporting facilitates rapid decision-making and compliance

Future Trends and Opportunities

Efforts to reduce sample preparation blank contamination could lower detection limits. Integration with automated sample prep and advanced data analytics may further boost throughput and reproducibility. Expanding screening to a broader range of excipients and nitrosamine precursors will strengthen supply-chain risk management.

Conclusion

The ACQUITY QDa II Mass Detector combined with a six-minute UHPLC method delivers robust, reliable nitrite quantitation in pharmaceutical excipients. High throughput, low maintenance, and strong precision make this workflow an effective tool for routine excipient screening and nitrosamine risk mitigation.

References

1. Brambilla G, Martelli A. Genotoxic and carcinogenic risk to humans of drug-nitrite interaction products. Mutat Res Rev Mutagen. 2007;635(1):17–52.
2. Horne S et al. Regulatory experiences with root causes and risk factors for nitrosamine impurities in pharmaceuticals. J Pharm Sci. 2023;112(5):1166–1182.
3. Cioc RC et al. Formation of N-Nitrosamine drug substance related impurities in medicines: regulatory perspective. Org Process Res Dev. 2023.
4. Wu Y et al. Reactive impurities in excipients: profiling, identification and mitigation. AAPS PharmSciTech. 2011;12(4):1248–1263.
5. Berardi A et al. Modeling the impact of excipient selection on nitrosamine formation. Pharmaceutics. 2023;15(8):2015.
6. Boetzel R et al. A nitrite excipient database to support N-nitrosamine risk assessments. J Pharm Sci. 2023;112(6):1615–1624.
7. Wang QH et al. Methods for the detection and determination of nitrite and nitrate: a review. Talanta. 2017;165:709–720.
8. Jireš J, Douša M. Nitrites as precursors of N-nitrosation in pharmaceutical samples – a trace level analysis. J Pharm Biomed Anal. 2022;213:114677.